Document is current
Any future updates will be listed below
-
Authors
Wang, Runhua
Ma, Rong
Cai, Yuanyuan
Zhang, Liling
Lu, Weicong
Zheng, Wenjing
Kong, Jiehua
Miao, Qingzhe
Li, Xiaoyue
Guan, Lijie
Gao, Yanling
Chen, Kun
Kwan, Angela T. H.
McIntyre, Roger S.
Xu, Guiyun
Yu, Calvin Kai-Ching
Lam, Bess Yin-Hung
So, Kwok-Fai
Lin, Kangguang
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Guangdong Province (No. 2021A1515011361)
Science and Technology Program of Guangzhou (No. 202102020735)
Guangzhou Key Clinical Specialty
Guangzhou Medical University Research Capacity Enhancement Program (No. 2024SRP208)
Science and Technology Program of Guangzhou, China (No. 202007030012)
Science and Technology Program of Guangzhou, China (No. 202007030012)
National Natural Science Foundation of China (No. 82171531)
Guangzhou Medical University student innovation ability enhancement Program (No. PX-66221557)
the Hong Kong RGC theme-based Strategic Target Grant Scheme (STG STG1/M-501/23-N)
- License Information
-
More Information
Article History
Received: 15 June 2025
Accepted: 9 March 2026
First Online: 24 March 2026
Competing interests
: Financial and Non-Financial Interest: Roger McIntyre has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, AbbVie, Atai Life Sciences. Roger McIntyre is the CEO of Braxia Scientific Corp. The other authors do not have a competing interest.
